Dal Maso, Luigino; Panato, Chiara; Tavilla, Andrea; Guzzinati, Stefano; Serraino, Diego; Mallone, Sandra; Botta, Laura; Boussari, Olayidé; Capocaccia, Riccardo; Colonna, Marc; +15 more... Crocetti, Emanuele; Dumas, Agnes; Dyba, Tadek; Franceschi, Silvia; Gatta, Gemma; Gigli, Anna; Giusti, Francesco; Jooste, Valerie; Minicozzi, Pamela; Neamtiu, Luciana; Romain, Gaëlle; Zorzi, Manuel; De Angelis, Roberta; Francisci, Silvia; EUROCARE-5 Working Group; (2020) Cancer cure for 32 cancer types: results from the EUROCARE-5 study. International Journal of Epidemiology, 49 (5). pp. 1517-1525. ISSN 0300-5771 DOI: https://doi.org/10.1093/ije/dyaa128
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
BACKGROUND: Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. METHODS: 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15-74 years in 1990-2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. RESULTS: LEF ranged from 10 years for chronic lymphocytic leukaemia patients to <6 months for those with liver, pancreas, brain, gallbladder and lung cancers. It was 7.7 years for patients with prostate cancer at age 65-74 years and >5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and <10% for liver, lung and pancreatic cancers. TTC was <5 years for testis and thyroid cancer patients diagnosed below age 55 years, and <10 years for stomach, colorectal, corpus uteri and melanoma patients of all ages. For breast and prostate cancers, a small excess (CRS < 95%) remained for at least 15 years. CONCLUSIONS: Estimates from this analysis should help to reduce unneeded medicalization and costs. They represent an opportunity to improve patients' quality of life.
Item Type | Article |
---|---|
Faculty and Department | Faculty of Epidemiology and Population Health > Dept of Non-Communicable Disease Epidemiology |
Research Centre | Cancer Survival Group |
PubMed ID | 32984907 |
Elements ID | 151590 |
Download
Filename: Maso_etal_2022_Cancer-cure-for-32-cancer.pdf
Description: This is an author accepted manuscript version of an article accepted for publication, and following peer review. Please be aware that minor differences may exist between this version and the final version if you wish to cite from it.
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Download